Bio-Rad Laboratories BIO
$358.90 −$8.60 (-2.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $358.90 0.00%
Open$364.34
Prev close$367.50
Day range$353.31 – $369.44
Volume182.3K
Market cap$9.65B
P/E (TTM)9.5
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$656.40M+0.5% YoY
Operating profit$100,000.00-99.8% YoY
Net profit$458.60M+234.1% YoY
Diluted EPS$17.02+234.0% YoY
Free cash flow$65.20M-26.9% YoY
Operating cash flow$96.40M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin51.3%
Operating margin6.2%
Net margin39.5%
Return on equity14.3%
Return on assets10.0%
Return on invested capital11.6%
Current ratio3.18
Liabilities / assets29.5%
Cash & investments$1.66B
Total debt$1.33B
Net cash (debt)$332.70M
Free cash flow / sales12.7%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $656.40M | $651.00M | $592.10M | $2.58B | $693.20M |
| Total Operating Revenue | $656.40M | $651.00M | $592.10M | $2.58B | $693.20M |
| Cost of Revenue | $327.80M | $305.20M | $282.70M | $1.24B | $348.00M |
| Gross Profit | $328.60M | $345.80M | $309.40M | $1.34B | $345.20M |
| Operating Expense | $328.50M | $273.20M | $275.30M | $1.12B | $291.30M |
| Selling and Admin Expenses | $257.10M | $212.00M | $212.40M | $844.30M | $221.00M |
| Research & Development | $71.40M | $61.20M | $62.90M | $275.60M | $70.30M |
| Asset Impairment Loss | $0.00 | – | – | $1.40M | $0.00 |
| Operating Profit | $100,000.00 | $72.60M | $34.10M | $218.60M | $53.90M |
| Net Non-Operating Interest Income (Expense) | -$2.30M | $10.20M | $8.70M | $46.50M | $18.90M |
| Non-Operating Interest Income | $10.00M | $22.30M | $21.00M | $95.50M | $31.00M |
| Non-Operating Interest Expense | $12.30M | $12.10M | $12.30M | $49.00M | $12.10M |
| Other Income (Expense) | $540.90M | $459.30M | -$732.60M | $730.40M | $856.40M |
| Gain on Sale of Security | $590.20M | $458.50M | -$733.30M | $908.00M | $1.03B |
| Special Income (Charges) | -$49.80M | – | – | -$178.80M | -$172.80M |
| -Less:Impairment of Capital Assets | $49.80M | – | – | $172.80M | $172.80M |
| -Less:Write Off | $0.00 | – | – | $6.00M | $0.00 |
| Other Non-Operating Income (Expenses) | $500,000.00 | $800,000.00 | $700,000.00 | $1.20M | -$1.00M |
| Pretax Profit | $538.70M | $542.10M | -$689.80M | $995.50M | $929.20M |
| Tax | $80.10M | $170.70M | -$162.70M | $235.60M | $209.20M |
| Net Profit | $458.60M | $371.40M | -$527.10M | $759.90M | $720.00M |
| Profit from Continuing Operations | $458.60M | $371.40M | -$527.10M | $759.90M | $720.00M |
| Net Income to Parent Company | $458.60M | $371.40M | -$527.10M | $759.90M | $720.00M |
| Net Income to Common Stockholders | $458.60M | $371.40M | -$527.10M | $759.90M | $720.00M |
| Basic EPS | $17.13 | $13.89 | -$19.55 | $27.87 | $26.69 |
| Diluted EPS | $17.02 | $13.85 | -$19.55 | $27.85 | $26.65 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $10.78B | $10.25B | $9.79B | $10.58B | $10.58B |
| Total Current Assets | $3.08B | $3.02B | $2.94B | $2.91B | $2.91B |
| Cash and Cash Equivalents & Short-Term Investments | $1.66B | $1.62B | $1.56B | $1.54B | $1.54B |
| -Cash and Cash Equivalents | $465.30M | $517.00M | $507.20M | $529.80M | $529.80M |
| -Short Term Investments | $1.20B | $1.10B | $1.06B | $1.01B | $1.01B |
| Receivables | $422.60M | $441.80M | $426.20M | $460.60M | $460.60M |
| -Accounts Receivable | $422.60M | $441.80M | $426.20M | $460.60M | $460.60M |
| Prepaid Assets | $160.70M | $147.80M | $150.00M | $136.50M | $136.50M |
| Inventory | $783.90M | $780.60M | $770.50M | $740.70M | $740.70M |
| Other Current Assets | $47.10M | $31.80M | $30.70M | $27.70M | $27.70M |
| Total Non-Current Assets | $7.70B | $7.23B | $6.85B | $7.67B | $7.67B |
| Net PPE | $652.80M | $671.90M | $689.40M | $709.90M | $709.90M |
| -Gross PPE | $652.80M | $671.90M | $689.40M | $1.97B | $1.97B |
| Investments and Advances | $6.27B | $5.72B | $5.31B | $6.10B | $6.10B |
| Goodwill and Other Intangible Assets | $677.40M | $734.30M | $743.90M | $754.10M | $754.10M |
| -Goodwill | $573.00M | $574.30M | $577.10M | $579.80M | $579.80M |
| -Other Intangible Assets | $104.40M | $160.00M | $166.80M | $174.30M | $174.30M |
| Other Non-Current Assets | $101.10M | $101.70M | $102.80M | $102.70M | $102.70M |
| Total Liabilities | $3.18B | $3.08B | $2.94B | $3.12B | $3.12B |
| Total Current Liabilities | $969.10M | $961.30M | $917.00M | $517.00M | $517.00M |
| Payables | $171.30M | $217.70M | $178.00M | $165.60M | $165.60M |
| -Accounts Payable | $133.50M | $143.50M | $133.10M | $129.00M | $129.00M |
| -Total Tax Payable | $37.80M | $74.20M | $44.90M | $36.60M | $36.60M |
| Current Accrued Expenses | $210.30M | $150.50M | $148.40M | $172.30M | $172.30M |
| Short-Term Debt and Capital Lease Obligation | $432.70M | $434.30M | $436.70M | $37.40M | $37.40M |
| -Current Debt | $400.90M | $400.70M | $400.50M | $1.30M | $1.30M |
| -Current Capital Lease Obligation | $31.80M | $33.60M | $36.20M | $36.10M | $36.10M |
| Other Current Liabilities | $154.80M | $158.80M | $153.90M | $141.70M | $141.70M |
| Total Non-Current Liabilities | $2.21B | $2.12B | $2.02B | $2.61B | $2.61B |
| Long Term Debt and Capital Lease Obligation | $930.70M | $936.10M | $941.50M | $1.35B | $1.35B |
| -Long Term Debt | $803.10M | $803.00M | $802.90M | $1.20B | $1.20B |
| -Long Term Capital Lease Obligation | $127.60M | $133.10M | $138.60M | $145.70M | $145.70M |
| Non-Current Deferred Liabilities | $1.09B | $982.20M | $881.80M | $1.06B | $1.06B |
| Other Non-Current Liabilities | $190.90M | $198.50M | $198.40M | $197.80M | $197.80M |
| Total Equity | $7.60B | $7.17B | $6.85B | $7.45B | $7.45B |
| Stockholders' Equity | $7.60B | $7.17B | $6.85B | $7.45B | $7.45B |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $470.10M | $502.90M | $490.50M | $476.00M | $476.00M |
| Retained Earnings | $8.48B | $8.02B | $7.65B | $8.18B | $8.18B |
| Less: Treasury Stock | -$1.03B | -$1.08B | -$1.05B | -$1.01B | -$1.01B |
| Gains/Losses Not Affecting Retained Earnings | -$315.30M | -$271.30M | -$235.40M | -$189.10M | -$189.10M |
| -Accumulated Depreciation | – | – | – | -$1.26B | -$1.26B |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $96.40M | $98.70M | $108.10M | $532.20M | $164.90M |
| Net cash flow from continuing operations | $96.40M | $98.70M | $108.10M | $532.20M | $164.90M |
| Net Income from Continuing Operations | $458.60M | $371.40M | -$527.10M | $759.90M | $720.00M |
| Depreciation & Depletion & Amortization | $41.20M | $41.10M | $40.90M | $165.40M | $42.50M |
| Other Non-Cash Items | $6.10M | -$8.70M | $9.60M | -$3.30M | -$10.90M |
| Change in Working Capital | $113.40M | $138.40M | -$168.50M | $272.40M | $254.10M |
| -Change in Receivables | $18.80M | -$17.60M | $30.80M | $19.60M | $3.90M |
| -Change in Inventory | -$200,000.00 | -$7.80M | -$29.90M | $68.90M | $51.60M |
| -Change in Payables and Accrued Expense | -$34.70M | $64.40M | -$600,000.00 | $1.40M | $12.30M |
| -Change in Other Current Assets | -$6.00M | -$14.00M | -$4.80M | $12.20M | -$4.20M |
| -Change in Other Current Liabilities | $17.70M | $4.60M | $2.00M | -$200,000.00 | $300,000.00 |
| -Change In Other Working Capital | $117.80M | $108.80M | -$166.00M | $170.50M | $190.20M |
| Net cash flow from investing | -$145.90M | -$66.70M | -$93.20M | -$189.70M | -$34.20M |
| Net Cash Flow from Continuing Investing Activities | -$145.90M | -$66.70M | -$93.20M | -$189.70M | -$34.20M |
| Net PPE Purchase and Sale | -$31.20M | -$32.10M | -$29.90M | -$157.50M | -$45.80M |
| Net Business Purchase and Sale | $0.00 | – | – | -$218.50M | $0.00 |
| Net Investment Purchase and Sale | -$114.70M | -$35.70M | -$63.30M | $186.30M | $11.60M |
| Financing Cash Flow | -$1.60M | -$27.60M | -$44.00M | -$283.20M | $3.30M |
| Net Cash Flow from Continuing Financing Activities | -$1.60M | -$27.60M | -$44.00M | -$283.20M | $3.30M |
| Net Issuance Payments Of Debt | -$100,000.00 | -$200,000.00 | -$100,000.00 | -$500,000.00 | -$200,000.00 |
| Net Common Stock Issuance | $0.00 | -$31.50M | -$47.80M | -$295.50M | $0.00 |
| Proceeds from Stock Option Exercised | $3.60M | $4.20M | $3.90M | $15.80M | $3.90M |
| Net Other Financing Charges | -$5.10M | – | – | -$3.00M | -$400,000.00 |
| Ending Cash Balance | $467.10M | $518.80M | $509.00M | $532.20M | $532.20M |
| Net Change in Cash | -$51.10M | $4.40M | -$29.10M | $59.30M | $134.00M |
| Beginning Cash Balance | $518.80M | $509.00M | $532.20M | $489.80M | $398.20M |
| Effect of Exchange Rate Changes | -$600,000.00 | $5.40M | $5.90M | -$16.90M | $0.00 |
| Free Cash Flow | $65.20M | $66.70M | $78.10M | $374.60M | $119.10M |
| Net Intangibles Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on BIO.
Sign in to join the discussion.